MODULATING ROLE OF DOPAMINE ON ANESTHETIC REQUIREMENTS

I.S. Segal, M.D., I. Irwin, Ph.D., and M. Maze, M.B.

Department of Anesthesia, Stanford University, and Anesthesiology Service, Veterans Administration, Palo Alto, California 94304; and Institute for Medical Research, San Jose, California

Introduction: Endogenous and exogenous dopamine may be important determinants of anesthetic requirements. Administration of the dopamine agonist, apomorphine, increases pain threshold in rats in a dose-dependent manner. Levodopa (L-DOPA) administration decreased the halothane MAC in dogs although the mechanism for this change in anesthetic requirement is not known. In this investigation central nervous system dopamine was increased by exogenous levodopa (L-DOPA) and decreased by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). MPTP selectively destroys dopaminergic neurons of the substantia nigra in man and mice and induces a syndrome which has virtually all the functional and neurochemical features of idiopathic Parkinson's disease.

We have studied: 1) the mechanism for the MAC-reducing effect of dopamine; 2) the anesthetic requirements in an animal model of Parkinson's disease; and 3) whether anesthetic requirements are normalized in this animal model following repletion of dopamine with exogenous L-DOPA.

Methods: This study was approved by our institutional Animal Care and Use Committee. Male C57Bl/6jMr mice (9-12 months) were used in all the studies. L-DOPA, 5, 50 and 200 mg/kg, or its vehicle, was administered i.p. with carbidopa (CD) 25 mg/kg, a peripheral amino acid decarboxylase inhibitor, to prevent enzymatic conversion of L-DOPA to dopamine in peripheral tissue. MAC for halothane was then determined. The peripheral dopamine agonist, apomorphine, 0.25, 2.5, and 10 mg/kg, or its vehicle, ascorbate, was administered 30 min prior to determination of MAC to examine whether changes in MAC were mediated by central or peripheral dopamine receptors. The D1 dopamine agonist, SKF-83566, and D2 dopamine antagonist, (-)-sulpiride, were used to characterize the receptor subtype that mediated the L-DOPA changes in MAC. L-DOPA + CD were administered as described above and 45 min prior to determination of MAC, the dopamine agonists were administered. MPTP, 20 mg/kg or its vehicle, 0.9% saline, were administered i.p. and 7 days later MAC was determined. In separate experiments L-DOPA, 200 mg/kg + CD were administered to characterize the effects of repletion of striatal dopamine on MAC in MPTP-treated animals. Striatal dopamine was determined by electrochemical detection i) in control mice, ii) following L-DOPA, 200 mg/kg + CD administration in MPTP-treated mice. Analysis of variance (ANOVA) followed by Student's unpaired t-test with Bonferroni correction, were applied to evaluate the significance of the results. Each experiment was performed in duplicate using 12 mice for each treatment dose.

Results: L-DOPA dose-dependently decreased halothane MAC (p<0.05) (Figure 1) while dopamine, the peripheral dopamine agonist, was without effect. Administration of (-)-sulpiride (D2) antagonist blocked the MAC-reducing action of L-DOPA, while SKF-83566 (D1 antagonist) had no effect (Figure 1). MPTP increased the MAC for halothane by 37% (p<0.05) and decreased striatal dopamine by 82% (p<0.05). In MPTP-treated mice, repletion of dopamine with L-DOPA, 200 mg/kg, restored the MAC for halothane back to the control state. There was a highly significant negative correlation (r2=0.95) between striatal dopamine and halothane anesthetic requirements (Figure 2).

Discussion: These data suggest that central D2 dopamine receptors mediate the reduction of anesthetic requirements caused by L-DOPA, and that D2 striatal dopamine content is an important determinant of anesthetic requirements. Although the usual cautions should apply when extrapolating conclusions from an experimental to a clinical setting, we speculate that in the acute situation, anesthetic requirements in patients with Parkinson's disease will be altered by loss of substantia nigra neurons and L-DOPA treatment. Thus, careful titration of the anesthetic dose may be required to prevent under- or over-dosing with anesthetic agents in patients with Parkinson's disease.

Nicoll has suggested that general anesthesia produced by volatile agents is characterized electrophysiologically by membrane hyperpolarization through an increase in membrane potassium conductance. Dopamine acting on D2 receptors in the rat substantia nigra also caused membrane hyperpolarization by an increase in membrane potassium conductance. Thus, it is possible that dopamine agonists supplement the anesthetized state by membrane hyperpolarization, as a result of an increase in membrane potassium conductance mediated by D2 receptors in the central nervous system.

References:
3. Langston JW. Neurosci 8:79-83, 1983

Acknowledgements:
This work was supported in part by NIH RO1-GM30232.